Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +441494 818 025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Director
claire@zenopa.com
+441494 818 025

Testimonials
I want to take this opportunity to say “thank you” very much for all your help and support with my job searching. The professionalism that Zenopa showed me was also brilliant.
Suraj , 2014

Takeda commences phase III trial of prostate cancer drug

9 November 2010 00:00 in Pharmaceutical Company Product News


Takeda has announced the commencement of a phase III clinical study of a promising new treatment for prostate cancer.

In association with Millennium, its oncology-focused subsidiary, the company will conduct a global trial that will gauge the efficacy of TAK-700 with prednisone among chemotherapy-naive metastatic castration-resistant prostate cancer patients.

The non-steroidal androgen synthesis inhibitor has shown efficacy in preclinical studies by blocking a key enzyme in the testes and adrenal glands, with Takeda hoping it will deliver benefits in overall and progression-free survival rates.

In addition, a second phase III study, which will assess TAK-700 among patients that have progressed during or following docetaxel-based therapy, will open enrolment later in 2010.

Dr Nancy Simonian, chief medical officer at Millennium, said: "Our hope is that this trial will demonstrate strong levels of efficacy that address the unmet medical needs in advanced prostate cancer."

Last month, Takeda submitted an application to the European Medicines Agency for approval of azilsartan medoxomil, a new treatment for essential hypertension.ADNFCR-8000103-ID-800224423-ADNFCR

Other news stories from 09/11/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd